Open-Label, Multi-Center Phase I Dose Escalation Study with Lenalidomide In Patients with Acute Myeloid Leukemia

被引：0
|
作者：
Huetter, Marie-Luise [1 ]
Fiedler, Walter [2 ]
Kuendgen, Andrea [3 ]
Krauter, Juergen [4 ]
von Lilienfeld-Toal, Marie [5 ]
Kayser, Sabine [1 ]
Rafler, Heidi [1 ]
Doehner, Hartmut [1 ]
Schlenk, Richard F. [1 ]
机构：
[1] Univ Hosp Ulm, Ulm, Germany
[2] Univ Hosp Eppendorf, Hamburg, Germany
[3] Univ Hosp Dusseldorf, Dept Hematol & Oncol, Dusseldorf, Germany
[4] Hannover Med Sch, Klin Hamostasiol Onkol & Stammzelltransplant, D-30623 Hannover, Germany
[5] Univ Hosp Bonn, Dept Internal Med 3, Bonn, Germany
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1350 / 1351
页数：2
相关论文
共 50 条
  • [41] Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study
    Usuki, Kensuke
    Sakura, Toru
    Kobayashi, Yukio
    Miyamoto, Toshihiro
    Iida, Hiroatsu
    Morita, Satoshi
    Bahceci, Erkut
    Kaneko, Masahito
    Kusano, Mikiko
    Yamada, Shunsuke
    Takeshita, Shigeru
    Miyawaki, Shuichi
    Naoe, Tomoki
    [J]. CANCER SCIENCE, 2018, 109 (10): : 3235 - 3244
  • [42] A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
    Zonder, Jeffrey A.
    Mohrbacher, Ann F.
    Singhal, Seema
    van Rhee, Frits
    Bensinger, William I.
    Ding, Han
    Fry, John
    Afar, Daniel E. H.
    Singhal, Anil K.
    [J]. BLOOD, 2012, 120 (03) : 552 - 559
  • [43] Phase I/II open-label, dose-escalation trial of rituximab (Rituxan®) in patients with SLE.
    Anolik, JH
    Campbell, D
    Ritchlin, C
    Holyst, M
    Rosenfeld, S
    Sanz, I
    Young, F
    Felgar, R
    Kunkel, L
    Benyunes, M
    Grillo-Lopéz, A
    Rosenblatt, J
    Looney, RJ
    [J]. ARTHRITIS AND RHEUMATISM, 2000, 43 (12): : 2860 - 2860
  • [44] RESULTS OF A PHASE 2, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY OF LENALIDOMIDE IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
    O'Brien, Maureen
    Alonzo, Todd
    Cooper, Todd
    Levine, John
    Brown, Patrick
    Slone, Tamra
    Benettaib, Bouchra
    Biserna, Noha
    Poon, Jennifer
    Quan, Jackie
    Simcock, Mathew
    Weiss, Daniel
    Zimmerman, Linda
    Kolb, Edward
    [J]. PEDIATRIC BLOOD & CANCER, 2018, 65
  • [45] Combination of Bendamustine, Lenalidomide, and Dexamethasone (BLD) in Patients with Refractory or Relapsed Multiple Myeloma Is Safe and Highly Effective: Results of Phase I/II Open-Label, Dose Escalation Study
    Lentzsch, Suzanne
    O'Sullivan, Amy
    Kennedy, Ryan
    Abbas, Mohammad
    Gill, Navkiranjit
    Dai, Lijun
    Andreas, Carrie
    Gardner, Diane
    Pregja, Silvana Lalo
    Burt, Steve
    Redner, Robert L.
    Volkin, Robert
    Roodman, G. David
    Mapara, Markus Y.
    Viverette, J. Franklin
    Agha, Mounzer
    Waas, John K.
    Shuai, Yongli
    Normolle, Daniel
    Zonder, Jeffrey A.
    [J]. BLOOD, 2011, 118 (21) : 142 - 142
  • [46] Phase 2 dose multi-center, open-label study of ARQ 501, a checkpoint activator, in adult patients with persistent, recurrent or metastatic leiomyosarcoma (LMS)
    Hartner, L. P.
    Rosen, L.
    Hensley, M.
    Mendelson, D.
    Staddon, A. P.
    Chow, W.
    Kovalyov, O.
    Ruka, W.
    Skladowski, K.
    Jagiello-Gruszfeld, A.
    Byakhov, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] An open-label phase I/II dose escalation study of the treatment of pancreatic cancer using lithium gammalinolenate
    Fearon, KCH
    Falconer, JS
    Ross, JA
    Carter, DC
    Hunter, JO
    Reynolds, PD
    Tuffnell, Q
    [J]. ANTICANCER RESEARCH, 1996, 16 (02) : 867 - 874
  • [48] A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML)
    Pollyea, Daniel A.
    Kohrt, Holbrook E.
    Gallegos, Leonel
    Berube, Caroline
    Coutre, Steven
    Gotlib, Jason
    Liedtke, Michaela
    Mitchell, Beverly S.
    Medeiros, Bruno C.
    [J]. BLOOD, 2010, 116 (21) : 1347 - 1347
  • [49] A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma
    Shira Dinner
    Tamara J. Dunn
    Elizabeth Price
    Steven E. Coutré
    Jason Gotlib
    Caroline Berube
    Gregory P. Kaufman
    Bruno C. Medeiros
    Michaela Liedtke
    [J]. International Journal of Hematology, 2018, 108 : 267 - 273
  • [50] A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma
    Dinner, Shira
    Dunn, Tamara J.
    Price, Elizabeth
    Coutre, Steven E.
    Gotlib, Jason
    Berube, Caroline
    Kaufman, Gregory P.
    Medeiros, Bruno C.
    Liedtke, Michaela
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 108 (03) : 267 - 273
12345